Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Stanley TL, Fourman LT, Feldpausch MN, et al. The Lancet HIV 2019;6:e821-e830.
What it found
Liver fat fraction fell 4.1 percentage points more than with placebo (a 37% relative reduction). After 12 months, 35% on tesamorelin vs 4% on placebo had liver fat below 5%. Fasting glucose and HbA1c did not differ. More injection-site complaints with tesamorelin, none serious.
Limitations
Small trial (60 received study drug) in people with HIV and fatty liver; long-term effects on liver scarring were not established.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.